Skip to content

CD4-guided structured treatment interruptions safe in patients at high risk of resistance

Risk of resistance with nevirapine-containing HAART after pregnancy, even when stopped correctly

Substantial, but imperfect adherence a major risk factor for resistance amongst patients starting HAART

Resistance mutations persist for many years in untreated HIV-positive people

Low, detectable viral load on HAART associated with high levels of activated CD4 and CD8 T-cells

Low rate of treatment failure with tenofovir, 3TC and AZT

Treatment failure, not transmission, will be main source of drug resistant HIV in Africa in next 10 years

Drug-resistant virus acquired during HIV infection remains stable and persistent

AZT resistance suppression mutations can also reduce tenofovir resistance, test tube study shows (corrected)